- Revolutionary Sanitizer.
- Applied for GRAS status from FDA.
- Marvel of Engineering Technology.
Former Eastman Kodak Scientist Engineers Develop Liquid Germ Killer Hy-IQ™ Water to Revolutionize how Deadly Bacteria and Virus are EradicatedGood Lord. We’ve participated in nearly every intra-sector bull market since the ’70s, but we’ve never seen anything quite like the power moves, we’re seeing in this sector. Investors nimble enough to get in before their big moves have had the potential to make more money in the past 8 months, than in the prior 8 years!
In addition to peak gains from where we added them to the Watch List of 1,835% on Novavax, 1,511% on Co-Diagnostic – we’ve seen gains of 1,350% on Organicell and 1,028% on Immuron which we later added to the Watch List. That’s four ten-baggers in less than a year. Unheard of.
Moderna (MRNA) the chief wealth maker, has risen to a $28 billion valuation (sales of $60 million). Novovax (NVAX) which rose from a mere $3 to an eye-popping $178, is now valued at $9.8 billion (sales of $18 million). Vir Bio (VIR) is valued at $6.1 billion (sales $8 million). Inovio (INO) is valued at $3.1 billion has sales of $4 million. Co-Diagnostics a test kit maker with $200,000 in sales, didn’t make the billion club – but is valued at $700 million, so don’t feel too bad for them or their shareholders. Shareholders, who held have enjoyed the stock rise from the ashes at $0.90, to a subsequent high of $30. And this was despite a concerted short effort by Mark Cuban and Sharesleuth at $11. These are the good old days.
We’re adding Aphex BioCleanse Systems | Sunset Capital (OTCPK:SNST) to the Watch List. Aphex which recently went public via a reverse merger with Sunset Capital (OTCPK:SNST) is in our mind, clearly one of the most interesting stories out there.
Analyst's Disclosure: I am/we are long SNST.
Client, see report for detailed disclaimer and disclosure information.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.